Checkpoint Therapeutics (NASDAQ:CKPT) had its target price hoisted by HC Wainwright from $11.00 to $15.00 in a report issued on Wednesday, May 1st, The Fly reports. HC Wainwright currently has a buy rating on the stock.
A number of other research analysts have also commented on the company. Zacks Investment Research upgraded Checkpoint Therapeutics from a hold rating to a buy rating and set a $3.50 price objective on the stock in a research report on Wednesday, March 20th. ValuEngine lowered Checkpoint Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 2nd.
CKPT stock traded down $0.25 during midday trading on Wednesday, reaching $4.38. 94,176 shares of the company’s stock traded hands, compared to its average volume of 67,157. The stock has a market capitalization of $169.24 million, a price-to-earnings ratio of -3.45 and a beta of 4.51. Checkpoint Therapeutics has a 1-year low of $1.50 and a 1-year high of $5.20.
Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Checkpoint Therapeutics by 8.2% in the 1st quarter. Renaissance Technologies LLC now owns 124,404 shares of the company’s stock worth $356,000 after purchasing an additional 9,400 shares during the last quarter. Shepherd Kaplan Krochuk LLC boosted its position in shares of Checkpoint Therapeutics by 25.0% in the 4th quarter. Shepherd Kaplan Krochuk LLC now owns 50,000 shares of the company’s stock worth $91,000 after purchasing an additional 10,000 shares during the last quarter. Jefferies Group LLC bought a new position in shares of Checkpoint Therapeutics in the 1st quarter worth $36,000. Charles Schwab Investment Management Inc. bought a new position in shares of Checkpoint Therapeutics in the 1st quarter worth $48,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Checkpoint Therapeutics in the 4th quarter worth $36,000. Institutional investors and hedge funds own 8.34% of the company’s stock.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.
Recommended Story: FAANG Stocks
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.